Zinfandel New Public Database of Short Structural Variants Helps Researchers Pinpoint ALS Risk Marker Experts led by Duke neuroscientist Allen Roses developed the database hoping to boost researchers' ability to explore the role of short structural variants in complex diseases. Duke Researchers Present New Data on APOE/TOMM40 Algorithm for Alzheimer's MCI Risk Premium The group demonstrated the ability of a genetic algorithm to gauge whether cognitively normal people are at risk of near-term mental decline. Researchers Use APOE-TOMM40 Haplotypes to Explain African-Americans' Unique Alzheimer's Risk Profile Premium NEW YORK (GenomeWeb) – Using a new in-phase assay, researchers led by Duke University's Allen Roses believe they have captured key differences in APOE and TOMM40 haplotypes between African-American, Caucasian, and West African populations. Takeda, Zinfandel Launch TOMMORROW Trial to Evaluate Alzheimer's Onset Risk Algorithm, AD-4833 Premium This article has been updated from a previous version to correct the pioglitazone dose to be used in the TOMMORROW trial. It is 0.8 mg/day, not 0.6 mg/day. Originally published Sept. 3. Takeda, Zinfandel Evaluate Genetic Risk Algorithm Ahead of Alzheimer's Delay Study with Diabetes Rx Premium Originally published July 23. Jun 19, 2013 Innovation Boom or Bust? Industry Gauges Impact of SCOTUS Ruling on Gene Patents Premium Jul 25, 2012 Rodent Study Suggests Low-Dose Pioglitazone May Improve Cognitive Function in Alzheimer's Patients Premium Jan 12, 2011 Takeda to Use Zinfandel's TOMM40 Test in Alzheimer's Development Program for Actos Premium Jan 11, 2011 Takeda to Use Zinfandel TOMM40 Biomarker Assay for Alzheimer's Drug Study Jul 14, 2010 Brain Imaging, Cognitive Evaluation Link TOMM40 Alterations to Alzheimer's Risk in Healthy Patients Premium Jan 6, 2010 Researchers Publish Data on Gene Variant Associated with Late-Onset Alzheimer's Disease Premium Breaking News FDA Revises SARS-CoV-2 Test Emergency Use Authorization Requirements to Account for Variants Geisinger Wins $5M NIH Grant to Develop Point-of-Care Genetic Diagnostic Tool Second Genome, Virginia Commonwealth University Partner on NASH Biomarker Discovery LGC Receives CE Mark for AccuPlex SARS-CoV-2, Flu A/B, RSV Reference Material Kit Esophageal Cancer Testing Firm Lucid Diagnostics Files For IPO Twist Bioscience, DeepCDR Collaborate on Antibody Library Design The Scan Booster for At-Risk The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk. Preprints OK to Mention Again Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications. Hundreds of Millions More to Share The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post. Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.